Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine.
Webster R, Sekuloski S, Odedra A, Woolley S, Jennings H, Amante F, Trenholme KR, Healer J, Cowman AF, Eriksson EM, Sathe P, Penington J, Blanch AJ, Dixon MWA, Tilley L, Duffy MF, Craig A, Storm J, Chan JA, Evans K, Papenfuss AT, Schofield L, Griffin P, Barber BE, Andrew D, Boyle MJ, de Labastida Rivera F, Engwerda C, McCarthy JS.
Webster R, et al. Among authors: cowman af.
BMC Med. 2021 Nov 22;19(1):293. doi: 10.1186/s12916-021-02150-x.
BMC Med. 2021.
PMID: 34802442
Free PMC article.
Clinical Trial.
BACKGROUND: There is a clear need for novel approaches to malaria vaccine development. We aimed to develop a genetically attenuated blood-stage vaccine and test its safety, infectivity, and immunogenicity in healthy volunteers. ...CONCLUSIONS: This study represents the fir …
BACKGROUND: There is a clear need for novel approaches to malaria vaccine development. We aimed to develop a genetically attenuated b …